X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs SUVEN LIFE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA SUVEN LIFE NATCO PHARMA/
SUVEN LIFE
 
P/E (TTM) x 19.8 17.6 112.8% View Chart
P/BV x 19.0 4.2 454.8% View Chart
Dividend Yield % 0.6 0.4 143.7%  

Financials

 NATCO PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
SUVEN LIFE
Mar-17
NATCO PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs877229 383.8%   
Low Rs424151 280.3%   
Sales per share (Unadj.) Rs223.442.7 523.2%  
Earnings per share (Unadj.) Rs31.16.9 453.5%  
Cash flow per share (Unadj.) Rs40.38.5 472.0%  
Dividends per share (Unadj.) Rs5.001.00 500.0%  
Dividend yield (eoy) %0.80.5 145.9%  
Book value per share (Unadj.) Rs219.552.4 418.9%  
Shares outstanding (eoy) m33.07127.28 26.0%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.94.4 65.5%   
Avg P/E ratio x20.927.7 75.5%  
P/CF ratio (eoy) x16.122.2 72.6%  
Price / Book Value ratio x3.03.6 81.8%  
Dividend payout %16.114.6 110.2%   
Avg Mkt Cap Rs m21,50424,158 89.0%   
No. of employees `000NA1.0 0.0%   
Total wages/salary Rs m1,128522 216.2%   
Avg. sales/employee Rs ThNM5,349.7-  
Avg. wages/employee Rs ThNM513.5-  
Avg. net profit/employee Rs ThNM858.1-  
INCOME DATA
Net Sales Rs m7,3895,435 135.9%  
Other income Rs m167211 79.2%   
Total revenues Rs m7,5565,646 133.8%   
Gross profit Rs m1,7931,291 138.9%  
Depreciation Rs m304214 142.2%   
Interest Rs m36657 644.7%   
Profit before tax Rs m1,2901,231 104.8%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309359 86.0%   
Profit after tax Rs m1,027872 117.8%  
Gross profit margin %24.323.7 102.2%  
Effective tax rate %23.929.2 82.1%   
Net profit margin %13.916.0 86.7%  
BALANCE SHEET DATA
Current assets Rs m3,6814,917 74.9%   
Current liabilities Rs m3,1231,186 263.3%   
Net working cap to sales %7.668.6 11.0%  
Current ratio x1.24.1 28.4%  
Inventory Days Days8962 144.0%  
Debtors Days Days5931 190.7%  
Net fixed assets Rs m7,6853,154 243.6%   
Share capital Rs m331127 259.8%   
"Free" reserves Rs m6,6706,543 101.9%   
Net worth Rs m7,2596,670 108.8%   
Long term debt Rs m955259 368.3%   
Total assets Rs m11,9578,157 146.6%  
Interest coverage x4.522.7 20.0%   
Debt to equity ratio x0.10 338.4%  
Sales to assets ratio x0.60.7 92.7%   
Return on assets %11.711.4 102.4%  
Return on equity %14.213.1 108.3%  
Return on capital %20.718.6 111.5%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,4454,996 69.0%   
Fx outflow Rs m703959 73.3%   
Net fx Rs m2,7434,037 67.9%   
CASH FLOW
From Operations Rs m1,4401,088 132.3%  
From Investments Rs m-1,089-3,107 35.1%  
From Financial Activity Rs m-353-300 117.5%  
Net Cashflow Rs m-1-2,319 0.1%  

Share Holding

Indian Promoters % 52.0 63.4 82.1%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 0.0 -  
FIIs % 16.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 36.5 71.2%  
Shareholders   25,395 37,287 68.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  TTK HEALTHCARE  MERCK LTD  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Trade War Fears; Widening of Trade Deficit and Top Stocks in Action Today(Pre-Open)

Indian share markets trimmed their day's losses and ended flat on Friday amid weakness in their Asian peers, that wobbled on Friday as investors braced for US tariffs against China.

Related Views on News

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6%

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jun 15, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS